Skip to main content
Top
Published in: International Journal of Diabetes in Developing Countries 3/2011

01-09-2011 | Letter to Editor

Disguised fasting for fasting blood glucose determination: how about its actual incidence?

Author: Viroj Wiwanitkit

Published in: International Journal of Diabetes in Developing Countries | Issue 3/2011

Login to get access

Excerpt

Sir, fasting blood glucose determination is a widely used endocrine and metabolic testing in medical practice. This test is a routine investigation in follow-up evaluation of diabetes mellitus in many countries. The critical point for performing this test is a good patient preparation, fasting [1]. The problems arising out of improper fasting practices can be expected. Here, the author would like to draw attention to the problem of disguised fasting in actual clinical practice. The author verbally inquired into the fasting practice followed by 300 diabetic patients who visited to the diabetic clinic for follow-up. All cases got the fasting blood determination at a certified clinical pathology laboratory. Of interest, the author found that 12 patients (4%) reported that they did not perform correct fasting (three with no fasting and nine with incorrect fasting). Hence, a considerable rate of disguising of fasting sample can be seen. This can affect treatment strategy if the general practitioners do not make a note of this fact. The improper decision may be taken to adjust the antidiabetic regimen corresponding to the disguised high fasting blood glucose. In fact, although the laboratory has good quality system, it cannot correct the pre-analytical problem such as poor patient preparation [2]. Since the checking for fasting state is usually verbal, the disguising can be expected. Due to this reason, the actual rate of disguising might be higher than 4%. Some patients might also disguise to both laboratory and physician. The practice of using hemoglobin A1C for follow-up of diabetics, resolves such an issue completely [3]. …
Literature
1.
go back to reference Brigden ML, Heathcote JC. Problems in interpreting laboratory tests. What do unexpected results mean? Postgrad Med. 2000;107:145–6, 151–2, 155–8. Brigden ML, Heathcote JC. Problems in interpreting laboratory tests. What do unexpected results mean? Postgrad Med. 2000;107:145–6, 151–2, 155–8.
2.
go back to reference Wiwanitkit V. Types and frequency of preanalytical mistakes in the first Thai ISO 9002:1994 certified clinical laboratory, a 6-month monitoring. BMC Clin Pathol. 2001;1:5.PubMedCrossRef Wiwanitkit V. Types and frequency of preanalytical mistakes in the first Thai ISO 9002:1994 certified clinical laboratory, a 6-month monitoring. BMC Clin Pathol. 2001;1:5.PubMedCrossRef
3.
go back to reference Russell-Minda E, Jutai J, Speechley M, Bradley K, Chudyk A, Petrella R. Health technologies for monitoring and managing diabetes: a systematic review. J Diabetes Sci Technol. 2009;3:1460–71.PubMed Russell-Minda E, Jutai J, Speechley M, Bradley K, Chudyk A, Petrella R. Health technologies for monitoring and managing diabetes: a systematic review. J Diabetes Sci Technol. 2009;3:1460–71.PubMed
Metadata
Title
Disguised fasting for fasting blood glucose determination: how about its actual incidence?
Author
Viroj Wiwanitkit
Publication date
01-09-2011
Publisher
Springer-Verlag
Published in
International Journal of Diabetes in Developing Countries / Issue 3/2011
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-011-0029-z

Other articles of this Issue 3/2011

International Journal of Diabetes in Developing Countries 3/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.